AUXLY CANNABIS Forum: Community User: JanPreuss

Naja mit 1,05 sind wir ja immer noch im grünen Bereich diese Woche ... alles wird gut :) Hoffe ich ;)

Als psychologische Grenze, könnte nen Kaufsignal sein und lässt es nächste Woche evtl. wieder nen Stück steigen. Lieber langsam und stetig als jeden Tag große Sprünge

Und was hast du mit 1,10€ im Wochenende? Im Grunde ist es doch Wurst ob wir aktuell bei 1,50 oder 80 Cent stehen. Ab Juni wird es spannend und dann ist alles möglich, nach unten wie oben :D

Versteh das nicht... So gute news.. Und das ding geht runter.. Wenn es wenigsten stehen bliebe... Scheiß shorter

Wäre eigentlich ganz gut wenn wir mit der 1,10€ ins Wochenende gehen würden.

Warum shorten die...

Da wird geshortet was das zeug hält. Ich bin mehr als überzeugt von cbw. Das einzige was nicht absehbar ist, sind die verkaufspreise. Ansonsten ist cbw sehr gut aufgestellt.

Betrifft alle Titel. Die Kräfte dahinter würde ich wirklich gern verstehen.

und wieder runter.... :)

Ja top .immer weiter und weiter :)

dosecann nd somit ach deren anlage wurde von cbw in form von aktien aufgekauft.

Verstehe den Inhalt nicht zu 100%. Kann das kurz jemand in 3 Sätzen erklären?

Nicht schlecht....

Läuft

Cannabis Wheaton Announces Closing of Dosecann Acquisition V.CBW | 23 minutes ago VANCOUVER, British Columbia, May 17, 2018 (GLOBE NEWSWIRE) -- Cannabis Wheaton Income Corp. (TSX-V:CBW) ("Cannabis Wheaton" or the "Company") is pleased to announce that it has closed its previously announced acquisition (the “Transaction”) of all of the outstanding securities of Dosecann Inc. (“Dosecann”), a late-stage “Licensed Dealer” applicant pursuant to the Narcotic Control Regulations (the “NCR”).  Located in the biotech hub of Charlottetown, Prince Edward Island, Dosecann is currently completing the buildout of a 42,000 square foot facility, purpose-built for the research, development, extraction, formulation, filling and packaging of cannabis-based products. Upon receipt of regulatory approval, Dosecann will leverage its state-of-the-art facility to begin developing a range of value added cannabis-based products for the Company and its streaming partners to ultimately be sold to medical cannabis patients and, upon approval, into the natural health product and adult-use cannabis markets. Pursuant to the acquisition agreement dated April 3, 2018, the Company has acquired all of the outstanding securities of Dosecann (the “Dosecann Securities”) by way of a “three-cornered amalgamation” (the “Acquisition”) for an aggregate purchase price of up to $38,000,000, payable in common shares of the Company to the holders of the Dosecann Securities (the “Consideration Shares”), subject to the satisfaction of certain post-closing time and performance-based milestones. As part of the Acquisition, all outstanding convertible securities of Dosecann have either been converted into Dosecann common shares and exchanged for Consideration Shares or have otherwise been exchanged for convertible securities of Cannabis Wheaton based on the exchange ratio used in the Acquisition. The Company has issued 24,494,496 Consideration Shares at a deemed price of $1.47, of which 9,630,947 are subject to performance based milestone release. In addition, the Company has assumed the obligations of the existing Dosecann common share purchase warrants, resulting in the issuance of 5,071,248 common share purchase warrants in the capital of the Company (the “Replacement Warrants”). Each whole Replacement Warrant entitles the holder to purchase one common share of the Company at an exercise price of $0.962 until January 2020. As a result of the closing of the Transaction, Dosecann is now a wholly-owned subsidiary of the Company. Upon receipt of a Dealer’s Licence pursuant to the NCR, Dosecann will serve a critical role in the “mid-stream” segment of Cannabis Wheaton’s platform. Dosecann will be the Company’s primary facility for various value enhancing intellectual property related activities such as extraction, processing, branding and licensing, product development and manufacturing, research and development, and various international opportunities. The Company also intends to utilize the Dosecann facility for the commercialization of various cannabis products available under the Company’s recently announced license agreement with Dixie Brands, Inc., as permitted by applicable law. Hugo Alves, President and Director of Cannabis Wheaton stated, “The addition of Dosecann to the Cannabis Wheaton platform provides us with a strategic regulatory tool that we believe will be increasingly important under the proposed Cannabis Act. We couldn’t be more excited to be working with the high caliber team Greg Boone has put together to develop Dosecann into a true ‘center of excellence’ in the creation of intellectual property, product development and commercialization. We believe the Dosecann team’s proven ability to take pharmaceutical, natural health products, and consumer packaged goods from conceptualization to commercialization will be of huge value to the Company’s wholly owned subsidiaries and streaming partners as we enter the next leg of growth in the domestic and international markets for cannabis products.” Greg Boone, Founder and CEO of Dosecann commented, “The Dosecann team is delighted to partner with Cannabis Wheaton as we near the completion and licensing of our purpose-built facility. Given their in-depth industry knowledge and exceptionally strong management team, we believe Cannabis Wheaton is the perfect partner to bring Dosecann’s unique product formulations to market. We look forward to collaborating with Hugo and his team going forward.” Dr. Christina Woollard, Dosecann’s Chief Science Officer states, “I joined Dosecann because I was confident that Dosecann would play a significant role in the Canadian cannabis industry. I have dedicated my career to the study and commercialization of patient focused medicines and I look forward to leveraging my 18 years of experience as the Head of Pharmaceutical Development for GW Pharmaceuticals to help Dosecann become the benchmark cannabis manufacturing and development facility in Canada.”  

den haschis ist manchmal nicht zu trauen:))))))))))))))